Showing results (71-80 of 238) with videos related to

Sort By:
Pageof 24
Science Translational Medicine|April 1, 2016
Somatic PIK3CA mutations as a driver of sporadic venous malformationsPau Castel, F Javier Carmona, Joaquim Grego-Bessa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2016
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast CancerJosé Baselga, Gail D Lewis Phillips, Sunil Verma, et al.
Science (New York, N.Y.)|March 25, 2017
PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2DEneda Toska, Hatice U Osmanbeyoglu, Pau Castel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2010
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapyJosé Baselga, Karen A Gelmon, Shailendra Verma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2010
Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumorsJosé Baselga, Andres Cervantes, Erika Martinelli, et al.
Cancer Research|October 28, 2010
A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancersJosep Lluís Parra-Palau, Kim Pedersen, Vicente Peg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2006
Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinomaFederico Rojo, Josep Tabernero, Joan Albanell, et al.
The Oncologist|January 26, 2019
Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2Aleix Prat, Jan Christoph Brase, Yuan Cheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2012
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 StudyKimberly L Blackwell, Harold J Burstein, Anna Maria Storniolo, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 31, 2018
Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencingDara S Ross, Ahmet Zehir, Edi Brogi, et al.
Pageof 24